Skip to main content
Premium Trial:

Request an Annual Quote

South Carolina Lab to Use Part of $2M NOAA Grant to Study Seafood Quality

NEW YORK, Nov. 30 (GenomeWeb News) - The Hollings Marine Laboratory in South Carolina will use part of a $2.05 million grant from the National Oceanic and Atmospheric Administration to develop genomic techniques to study seafood quality, the lab said today.

As part of the grant, Hollings will create the Applied Marine Genomics research group, which will develop "genetic techniques for evaluating the molecular-level responses of oysters and shrimp to multiple environmental stressors," according to the lab.

The Marine Genomics group will be led by Bob Chapman of the South Carolina Department of Natural Resources and Greg Warr of the Medical University of South Carolina. Two researchers, Karen Burnett and Lou Burnett of the Collegeof Charleston, will study whether "multiple stressors, such as low levels of dissolved oxygen and chemicals, affect the degree to which oysters are vectors for human pathogens.


The research is part of NOAA's new "Oceans and Human Health Initiative," a program anticipated to last at least five years. NOAA is an agency of the US Department of Commerce.

 

The Hollings lab also plans to establish a group to study chemical contaminants and source tracking of marine pathogens.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.